Salud financiera de hoja de balance de CANbridge Pharmaceuticals

Salud financiera controles de criterios 0/6

CANbridge Pharmaceuticals tiene un patrimonio de los accionistas total de CN¥-280.2M y una deuda total de CN¥45.8M, lo que sitúa su ratio deuda-patrimonio en -16.3%. Sus activos y pasivos totales son CN¥248.9M y CN¥529.2M respectivamente.

Información clave

-16.3%

Ratio deuda-patrimonio

CN¥45.81m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	CN¥49.10m
Patrimonio	-CN¥280.24m
Total pasivo	CN¥529.19m
Activos totales	CN¥248.95m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

CANbridge Pharmaceuticals Inc. (HKG:1228) Not Doing Enough For Some Investors As Its Shares Slump 28%

Nov 14

CANbridge Pharmaceuticals Inc. (HKG:1228) Stock Catapults 31% Though Its Price And Business Still Lag The Industry

Sep 27

Lacklustre Performance Is Driving CANbridge Pharmaceuticals Inc.'s (HKG:1228) 28% Price Drop

Aug 07

CANbridge Pharmaceuticals Inc.'s (HKG:1228) Share Price Boosted 56% But Its Business Prospects Need A Lift Too

Apr 23

CANbridge Pharmaceuticals Inc.'s (HKG:1228) 26% Dip In Price Shows Sentiment Is Matching Earnings

May 05

Análisis de la situación financiera

Pasivos a corto plazo: 1228 tiene patrimonio neto negativo. Es una situación más grave que activos a corto plazo que no cubren pasivos a corto plazo.

Pasivo a largo plazo: 1228 tiene patrimonio neto negativo. Esta situación es más grave que el hecho de que los activos a corto plazo no cubran los pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: 1228 tiene patrimonio negativo, una situación más grave que un alto nivel de endeudamiento.

Reducción de la deuda: 1228 tiene patrimonio neto negativo, por lo que no necesitamos comprobar si su deuda se ha reducido con el tiempo.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: 1228 tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: 1228 tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 1.2% cada año

Salud financiera de hoja de balance de CANbridge Pharmaceuticals

Salud financiera controles de criterios 0/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

New major risk - Market cap size

CANbridge Pharmaceuticals Inc. (HKG:1228) Not Doing Enough For Some Investors As Its Shares Slump 28%

First half 2024 earnings released: CN¥0.58 loss per share (vs CN¥0.51 loss in 1H 2023)

CANbridge Pharmaceuticals Inc. (HKG:1228) Stock Catapults 31% Though Its Price And Business Still Lag The Industry

CANbridge Pharmaceuticals Inc. Announces Board and Board Committee Changes

CANbridge Pharmaceuticals Inc. to Report First Half, 2024 Results on Aug 29, 2024

Lacklustre Performance Is Driving CANbridge Pharmaceuticals Inc.'s (HKG:1228) 28% Price Drop

Consensus EPS estimates fall by 23%

Price target decreased by 21% to HK$7.00

Consensus EPS estimates upgraded to CN¥0.59 loss

CANbridge Pharmaceuticals Inc.'s (HKG:1228) Share Price Boosted 56% But Its Business Prospects Need A Lift Too

Full year 2023 earnings: EPS and revenues exceed analyst expectations

CANbridge Pharmaceuticals Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

CANbridge Pharmaceuticals Inc. Announces Resignation of Derek Paul Di Rocco as Non-Executive Director and A Member of the Nomination and Corporate Governance Committee

CANbridge Pharmaceuticals Inc. to Present Fabry Disease Gene Therapy Abstract At Esgct 30Th Annual Congress

CANbridge Announces NDA Acceptance of CAN108 (???®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China's National Medical Products Administration

Canbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in the Core Part of the Can103 Phase 2 Trial for Gaucher Disease in China

Canbridge Pharmaceuticals Inc. Announces Marketing Approval of Can108 (Maralixibat Chloride Oral Solution /Livmarli®?) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (Algs)

First half 2023 earnings released: CN¥0.51 loss per share (vs CN¥0.59 loss in 1H 2022)

CANbridge Pharmaceuticals Inc. to Report First Half, 2023 Results on Aug 30, 2023

Price target decreased by 82% to HK$1.70

Consensus revenue estimates decrease by 22%, EPS upgraded

New minor risk - Share price stability

CANbridge Pharmaceuticals Inc. Announces Preliminary Clinical Data of Phase 1B Study of Omoprubart (CAN106) in Paroxysmal Nocturnal Hemoglobinuria (PNH)

Consensus EPS estimates upgraded to CN¥1.05 loss

CANbridge Pharmaceuticals, Inc. Announces Marketing Approval of CAN108 (LIVMARLI) in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

CANbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in China Region of the Global LIVMARLI(R) (CAN108) EMBARK Phase 2 Study in Biliary Atresia

CANbridge Pharmaceuticals Inc.'s (HKG:1228) 26% Dip In Price Shows Sentiment Is Matching Earnings

Full year 2022 earnings: EPS and revenues exceed analyst expectations

CANbridge Pharmaceuticals Inc. Announces First Patient Dosed in CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in China

High number of new and inexperienced directors

First half 2022 earnings released: CN¥0.59 loss per share (vs CN¥46.79 loss in 1H 2021)

CANbridge Pharmaceuticals Inc. to Report First Half, 2022 Results on Aug 24, 2022

Canbridge Pharmaceuticals Inc. Announces First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 1/2 Trial for the Treatment of Gaucher Disease in China

CANbridge Pharmaceuticals Inc. Announces First Patient Dosed in CAN108 (Maralixibat) EMBARK Phase 2 Study in Biliary Atresia in China

CANbridge Pharmaceuticals Inc. Forms Scientific Advisory Board

Canbridge Pharmaceuticals Inc. Announces Board Changes

CANbridge Pharmaceuticals Inc. Announces Results from its CAN106 Phase 1 Trial

CANbridge Pharmaceuticals Inc. Appoints Pauline Li as Senior Vice President of Clinical Development and Operations

High number of new and inexperienced directors

CANbridge Pharmaceuticals Inc. Announces Executive Changes

CANbridge Pharmaceuticals Inc. Announces First Patient Has Been Dosed in the Can106 Phase 1B/2 Trial for Treatment of Paroxysmal Nocturnal Hemoglobinuria in China

Canbridge Pharmaceuticals Inc. Announces Approval of Can108 for Rare Liver Disease, Alagille Syndrome, Under the Early and Pilot Implementation Policy in Boao Lecheng International Medical Tourism Pilot Zone

CANbridge Pharmaceuticals Inc. Announces Board Changes

CANbridge Pharmaceuticals Inc. Reports Positive Top-Line Can106 Phase 1 Data

CANbridge Pharmaceuticals CAN108 New Drug Application (NDA) for Alagille Syndrome Accepted by China’s National Medical Products Administration

CANbridge Pharmaceuticals Inc. has completed an IPO in the amount of HKD 685.13718 million.

Less than half of directors are independent

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera